Rating |
SUBSCRIBE
(Long Term Only) |
Issue Offer | |
Issue Opens on | Nov 30, 2021 |
Issue Close on | Dec 02, 2021 |
Total IPO size (cr) | 7,249.18 |
Fresh issue | 2000.00 |
Offer For Sale (cr) | 5,249.18 |
Price Band (INR) | 870-900 |
Market Lot | 16 |
Face Value (INR) | 10 |
Retail Allocation | 10% |
Listing On | NSE, BSE |
Objects of the issue
⮚ To augment the company’s capital base and insolvency level. |
Issue Break-up (%) | |
QIB Portion | 75 |
NIB Portion | 15 |
Retail Portion | 10 |
Shareholding (No. of Shares) | |
Pre Issue | 553,289,944 |
Post Issue | 575,620,567 |
Indicative Timetable | |
Finalisation of Basis of Allotment | 07-12-2021 |
Refunds/Unblocking
ASBA Fund |
08-12-2021 |
Credit of equity shares to DP A/c | 09-12-2021 |
Trading commences | 10-12-2021 |
Star Health and Allied Insurance Company Ltd is one of the largest private health insurers in India with a market share of 15.8% in Fiscal 2021. From being the first standalone health insurance (“SAHI”) company established in India in 2006, it has grown into the largest SAHI company in the overall health insurance market in India, according to CRISIL Research.
Company offer a range of flexible and comprehensive coverage options primarily for retail health, group health, personal accident and overseas travel, which accounted for 87.9%, 10.5%, 1.6% and 0.01%, respectively, of their total Gross written premium (GWP) in Fiscal 2021. Individual agents are the primary distributors of the company’s health insurance plans, accounting for 78.9% of their GWP in Fiscal 2021. In addition, the company has successfully built one of India’s largest health insurance hospital networks, with 11,778 hospitals as of September 30, 2021.
⮚ Company consistently ranked first in the retail health insurance market in India based on retail health GWP over the last three Fiscal Years, according to CRISIL Research.
⮚ The retail health market segment is expected to emerge as a key growth driver for the overall health insurance industry in India after the COVID-19 crisis in India
⮚ As of September 30, 2021 its distribution network had grown to 779 health insurance branches spread across 25 states and 5 union territories in India.
⮚ The company has also successfully built one of the largest health insurance hospital networks in India, with 11,778 hospitals, of which 7,741 hospitals, or 65.7 percent of the total number of hospitals in their network, entered into pre-agreed arrangements with in Fiscal 2021.
Outlook & Valuation: The company has mixed set on financials over the last three years where the company’s GWP has increased over the years while the company suffered a loss in FY21. In FY19, the revenues of the company were Rs 3713 cr while in FY21 it grew to 5283 cr.
The Profit was at Rs 128 cr in FY19 while the company suffered a loss of Rs 825 cr in FY21. The health insurance sector is likely to flourish as individuals become more aware of the benefits of health insurance. If we look at the company’s financials, we can see that it was doing well until Covid hit last year. The company has the largest market share which is positive for the company however the industry is getting competitive.
The valuation of the company is stretched r. At the upper price band of Rs. 900, Star Health is demanding an MCAP to net premium earned multiple of 10.3x, which is at a premium to the peer average. Thus, we assign a “SUBSCRIBE” rating only for the long term.
www.swastika.co.in
For additional information & risk factors please refer to the Red Herring Prospectus
IPO Note
STAR HEALTH AND ALLIED INSURANCE COMPANY LTD IPO
KEY MANAGERIAL PERSONNEL
⮚ Venkatasamy Jagannathan is the Chairman and CEO of the Company. He holds master’s degree of arts in economics and have more than 47 years of experience in the insurance industry
⮚ Subbarayan Prakash is the Managing Director of the Company. He has several years of experience as a surgeon and has previously worked with Saudi Operation & Maintenance Company Limited.
⮚ Anand Shankar Roy is the Managing Director of our Company. He holds a bachelor’s degree in commerce and he has 21 years of experience in the insurance industry
⮚ Sumir Chadha is a Non-Executive Nominee Director of the Company he has several years of investing experience in Indian companies, both public and private.
⮚ Deepak Ramineedi is a Non-Executive Nominee Director of the Company. He has several years of experience in the private equity industry
⮚ Utpal Hemendra Sheth is a Non-Executive Nominee Director of the Company. He holds a bachelor’s degree in commerce.
⮚ Rohit Bhasin is an Independent Director of the Company
⮚ Anisha Motwani is an Independent Director of the Company.
⮚ Berjis Minoo Desai is an Independent Director of the Company
⮚ Kaarthikeyan Devarayapuram Ramasamy is an Independent Director of the Company
⮚ Rajni Sekhri Sibal is an Independent Director of the Company
⮚ Rajeev Krishnamuralilal Agarwal is an Independent Director of the Company
COMPETITIVE STRENGTHS
⮚ Largest private health insurance company in India with leadership in the attractive retail health segment. ⮚ Largest and well spread distribution network in the health insurance industry.
⮚ Diversified product suite with a focus on innovation and specialized products.
⮚ Strong risk management with superior claims ratio and quality customer services.
⮚ Substantial investment in technology and innovative business processes.
⮚ Demonstrated track record of operating and financial performance.
⮚ Experienced senior management team with strong sponsorship.
KEY CONCERNS
⮚ Star Health Incurred Claim Ratio has increased from average 63.5% (FY2018 to FY2020) to 94% in FY21 and 91% in Q1 FY22. This is the main reason company has negative revenues and losses in the last 1.5 years. ⮚ The recent Covid-19 outbreak has had a significant impact on the company’s business and operations. ⮚ They were able to keep their market share because of their strong brand name. However, if they fail to keep such a brand name, their business will suffer.
⮚ Company can be subject to claims by customers and/or regulators for alleged mis-selling. ⮚ Insurance companies depend on the accuracy and completeness of information provided by customers and counter parties for pricing and underwriting their insurance policies.
⮚ Any increase in competition could negatively impact the company’s profitability
www.swastika.co.in
For additional information & risk factors please refer to the Red Herring Prospectus
IPO Note
STAR HEALTH AND ALLIED INSURANCE COMPANY LTD IPO
COMPARISON WITH LISTED INDUSTRY PEERS (As on 31st March 2021)
Name of the Company | EPS (Basic) | NAV | P/E | Net Worth (cr) RoNW (%) | |
Star Health and Allied Insurance Co Ltd | (16.54) | 63.58 | – | 3,484.64 | (23.69)% |
Peer Group | |||||
ICICI Lombard General Insurance Co Ltd.* | 32.41 | 163.56 | 46.66 | 7,435.15 | 19.81% |
New India Assurance Co Ltd | 9.95 | 112.17 | 15.30 | 18,485.38 | 8.81% |
*ICICI Lombard General Insurance Company Ltd. is not strictly comparable with the Company as they operate under general insurance with health insurance not forming a significant component, whereas the Company is a standalone health insurance provider.
FINANCIALS (RESTATED CONSOLIDATED)
Particulars (Rs. In Cr) FY 2021 FY 2020 FY 2019 |
Equity Share Capital 548 491 456 |
Other Equity 3,676 1,153 587 |
Net Worth 4,224 1,644 1,043 |
Total Borrowings 250 250 250 |
Premiums earned (Net) 5,023 4,693 3,580 |
Operating Profit/(Loss) (1,071) 361 165 |
Profit Before Tax (1,046) 413 182 |
Net Profit for the year (825) 268 128 |
DISCLAIMER:
The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. (“SIL”). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus (“RHP”) issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor’s particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.
Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.
CORPORATE & ADMINISTRATIVE OFFICE – 48, Jaora Compound, M.Y.H. Road, Indore – 452 001 | Phone 0731 – 6644000
Compliance Officer: Ms. Sheetal Duraphe Email: compliance@swastika.co.inPhone: (0731) 6644 241
Swastika Investmart Limited, SEBI Reg. No. : NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532 CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.
www.swastika.co.in
For additional information & risk factors please refer to the Red Herring Prospectus